TP53 and ovarian carcinoma: In a single-arm phase 2 study, adavosertib was combined with carboplatin in TP53-mutated ovarian cancer refractory/resistant to platinum-based first-line treatment within three months, representing a patient population expected to have poor clinical outcomes.